Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Biologics and Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.1% during the forecast period.
This report presents the market size and development trends by detailing the Biologics and Biosimilars market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Biologics and Biosimilars market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Biologics and Biosimilars industry and will help you to build a panoramic view of the industrial development.
Biologics and Biosimilars Market, By Type:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Biologics and Biosimilars Market, By Application:
Tumor
Diabetes
Cardiovascular
Hemophilia
Some of the leading players are as follows:
Merck
3sbio
AbbVie
Eli Lilly
Novartis
Pfizer
Gelgen
CP Guojian
Dong Bao
Ganlee
Innovent
Johnson & Johnson
Roche
United Laboratories
Novo Nordisk
Sanofi-Aventis
Biotech
Amgen
Changchun High Tech
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Biologics and Biosimilars Market: Technology Type Analysis
-
4.1 Biologics and Biosimilars Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Biologics and Biosimilars Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Monoclonal Antibodies
4.3.2 Interferon
4.3.3 Erythropoietin
4.3.4 Insulin
4.3.5 Vaccines
5 Biologics and Biosimilars Market: Product Analysis
-
5.1 Biologics and Biosimilars Product Market Share Analysis, 2018 & 2026
-
5.2 Biologics and Biosimilars Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Biologics and Biosimilars Market: Application Analysis
-
6.1 Biologics and Biosimilars Application Market Share Analysis, 2018 & 2026
-
6.2 Biologics and Biosimilars Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Tumor
6.3.2 Diabetes
6.3.3 Cardiovascular
6.3.4 Hemophilia
7 Biologics and Biosimilars Market: Regional Analysis
-
7.1 Biologics and Biosimilars Regional Market Share Analysis, 2018 & 2026
-
7.2 Biologics and Biosimilars Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Merck
9.1.1 Merck Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 3sbio
9.2.1 3sbio Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 AbbVie
9.3.1 AbbVie Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Eli Lilly
9.4.1 Eli Lilly Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Novartis
9.5.1 Novartis Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Pfizer
9.6.1 Pfizer Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Gelgen
9.7.1 Gelgen Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 CP Guojian
9.8.1 CP Guojian Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Dong Bao
9.9.1 Dong Bao Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Ganlee
9.10.1 Ganlee Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Innovent
9.11.1 Innovent Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Johnson & Johnson
9.12.1 Johnson & Johnson Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Roche
9.13.1 Roche Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 United Laboratories
9.14.1 United Laboratories Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Novo Nordisk
9.15.1 Novo Nordisk Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Sanofi-Aventis
9.16.1 Sanofi-Aventis Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Biotech
9.17.1 Biotech Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
9.18 Amgen
9.18.1 Amgen Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis
9.19 Changchun High Tech
9.19.1 Changchun High Tech Company overview
9.19.2 Financial performance
9.19.3 Product benchmarking
9.19.4 Strategic initiatives
9.19.5 SWOT analysis
The List of Tables and Figures (Totals 104 Figures and 150 Tables)
Figure Monoclonal Antibodies Biologics and Biosimilars market, 2015 - 2026 (USD Million)
Figure Interferon Biologics and Biosimilars market, 2015 - 2026 (USD Million)
Figure Erythropoietin Biologics and Biosimilars market, 2015 - 2026 (USD Million)
Figure Insulin Biologics and Biosimilars market, 2015 - 2026 (USD Million)
Figure Vaccines Biologics and Biosimilars market, 2015 - 2026 (USD Million)
Figure Tumor market, 2015 - 2026 (USD Million)
Figure Diabetes market, 2015 - 2026 (USD Million)
Figure Cardiovascular market, 2015 - 2026 (USD Million)
Figure Hemophilia market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Biologics and Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table North America Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table North America Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table North America Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Canada Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Canada Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Europe Biologics and Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Europe Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Europe Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Europe Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Germany Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Germany Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table France Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table France Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Italy Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Italy Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Spain Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Spain Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biologics and Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table China Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table China Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Japan Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Japan Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table India Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table India Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Biologics and Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table MEA Biologics and Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table MEA Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table MEA Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table MEA Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Biologics and Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Biologics and Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Biologics and Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Merck Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table 3sbio Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AbbVie Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Gelgen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table CP Guojian Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dong Bao Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Ganlee Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Innovent Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table United Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sanofi-Aventis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biotech Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amgen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Changchun High Tech Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
